Going by the summary of Intel's appeal filed with the European Court of Justice in July, after being levied a record $1.45 billion fine in May, the chip giant has argued that the European Commission (EC) messed up the antitrust lawsuit, in which the company was accused of exploiting its leading market position in the personal-computer chip market.
As per the allegations leveled by the EC against Intel, the chip biggie was trying to oust rival Advanced Micro Devices Inc. (AMD) from the PC chip market. While announcing the unprecedented fine, EC had said that Intel's competition-thwarting practices were harming millions of European consumers "by deliberately acting to keep competitors out of the market for computer chips."
However, denying the charges, Intel's appeal summary - published recently in the official journal of the European Court of Justice - contended that the EC "ails to meet the required standard of proof in its analysis of the evidence."
In addition, Intel maintained that EC "infringed its right of defense" by refusing to grant it an oral hearing related to additional allegations; and also that EC failed to obtain some essentially relevant "internal documents from the competitor."
Requesting the court to terminate the EC ruling "whole or in part," Intel also asked for the cancellation or reduction of the fine imposed, and sought the payment of the company's expenses by the EC.
Popular content
Today's:
All time:
Last viewed:
- Low-Carb Diet Emerges as Best Remedy for Keeping Blood Pressure Levels Low
- China Seeking Mergers Abroad to Race Ahead of Competition at Home
- Vonage unveils apps for iPhone, iPod Touch and BlackBerry devices
- 5.1% Rise in Same Store Sales Reported by Wal-Mart de Mexico
- Swann Launches a Tirade against Pay Hike for Health Service Board Executives
- New Facebook privacy controls may help business users
- Mixing of Herbal Remedies and Heart Drugs May Get Dangerous
- ComScore releases its study on internet usage in France
- Hollywood puts RealDVD to test in court; Judge asks public to leave
- FDA Looking at Possibility of Administering Wider Use of Tarceva in Cases of Lung Cancer


























